NO940084L - Fremgangsmåte for behandling av motor-neuron sykdommer ved anvendelse av medlemmer av BDNF/NT-3/NGF familien av molekyler - Google Patents

Fremgangsmåte for behandling av motor-neuron sykdommer ved anvendelse av medlemmer av BDNF/NT-3/NGF familien av molekyler

Info

Publication number
NO940084L
NO940084L NO940084A NO940084A NO940084L NO 940084 L NO940084 L NO 940084L NO 940084 A NO940084 A NO 940084A NO 940084 A NO940084 A NO 940084A NO 940084 L NO940084 L NO 940084L
Authority
NO
Norway
Prior art keywords
bdnf
motor
ngf family
molecules
motor neuron
Prior art date
Application number
NO940084A
Other languages
English (en)
Norwegian (no)
Other versions
NO940084D0 (no
Inventor
Vivien Wong
Czeslaw Radziejewski
Peter Distefano
Original Assignee
Regeneron Pharma
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Max Planck Gesellschaft filed Critical Regeneron Pharma
Publication of NO940084D0 publication Critical patent/NO940084D0/no
Publication of NO940084L publication Critical patent/NO940084L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physical Water Treatments (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Water Treatment By Sorption (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO940084A 1991-07-10 1994-01-10 Fremgangsmåte for behandling av motor-neuron sykdommer ved anvendelse av medlemmer av BDNF/NT-3/NGF familien av molekyler NO940084L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72770491A 1991-07-10 1991-07-10
PCT/US1992/004228 WO1993001300A1 (en) 1991-07-10 1992-05-19 Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules

Publications (2)

Publication Number Publication Date
NO940084D0 NO940084D0 (no) 1994-01-10
NO940084L true NO940084L (no) 1994-03-08

Family

ID=24923677

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940084A NO940084L (no) 1991-07-10 1994-01-10 Fremgangsmåte for behandling av motor-neuron sykdommer ved anvendelse av medlemmer av BDNF/NT-3/NGF familien av molekyler

Country Status (20)

Country Link
EP (2) EP0593516B1 (da)
JP (1) JPH06509094A (da)
CN (1) CN1065768C (da)
AT (1) ATE202939T1 (da)
AU (2) AU675409B2 (da)
CA (1) CA2113083A1 (da)
DE (1) DE69231930T2 (da)
DK (1) DK0593516T3 (da)
ES (1) ES2157903T3 (da)
FI (1) FI940098A7 (da)
GR (1) GR3036776T3 (da)
HU (1) HUT70275A (da)
IE (1) IE921602A1 (da)
IL (1) IL101928A0 (da)
NO (1) NO940084L (da)
PT (1) PT100501A (da)
RU (1) RU94016525A (da)
SK (1) SK2694A3 (da)
WO (1) WO1993001300A1 (da)
ZA (1) ZA923639B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025684A1 (en) * 1992-06-12 1993-12-23 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on neurotrophin-4 expression
FR2717496B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
AU2001259453B2 (en) 2000-05-05 2006-08-31 Beth Israel Deaconess Medical Center Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis
WO2008156418A1 (en) * 2007-06-19 2008-12-24 Astrazeneca Ab A method for screening or diagnosis of postpolio syndrome and fibromyalgia
MX2010001395A (es) * 2007-08-10 2010-03-10 Regeneron Pharma Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano.
WO2014111525A2 (en) 2013-01-18 2014-07-24 Anaxomics Biotech, Sl New combination therapies for treating nervous system diseases
WO2016210325A1 (en) 2015-06-26 2016-12-29 C.R. Bard, Inc. Connector interface for ecg-based catheter positioning system
WO2023164311A2 (en) * 2022-02-28 2023-08-31 Bioincept, Llc Compositions and methods of treating amyotrophic lateral sclerosis (als) and related disorders
GB202303495D0 (en) * 2023-03-09 2023-04-26 Ucl Business Ltd Therapy for charcot-marie-tooth disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor

Also Published As

Publication number Publication date
HU9400063D0 (en) 1994-06-28
IE921602A1 (en) 1993-01-13
PT100501A (pt) 1993-09-30
AU2009592A (en) 1993-02-11
ATE202939T1 (de) 2001-07-15
GR3036776T3 (en) 2002-01-31
RU94016525A (ru) 1996-06-10
EP0593516A4 (en) 1995-01-18
NO940084D0 (no) 1994-01-10
JPH06509094A (ja) 1994-10-13
AU7067696A (en) 1997-01-16
SK2694A3 (en) 1995-02-08
DE69231930T2 (de) 2002-04-11
AU675409B2 (en) 1997-02-06
ZA923639B (en) 1993-02-24
FI940098A7 (fi) 1994-03-10
CA2113083A1 (en) 1993-01-21
WO1993001300A1 (en) 1993-01-21
EP0755682A1 (en) 1997-01-29
EP0593516A1 (en) 1994-04-27
HUT70275A (en) 1995-09-28
IL101928A0 (en) 1992-12-30
EP0593516B1 (en) 2001-07-11
DE69231930D1 (de) 2001-08-16
DK0593516T3 (da) 2001-09-17
CN1065768C (zh) 2001-05-16
CN1071585A (zh) 1993-05-05
ES2157903T3 (es) 2001-09-01
FI940098A0 (fi) 1994-01-10

Similar Documents

Publication Publication Date Title
Miwa et al. Lipopolysaccharide enhances synthesis of brain‐derived neurotrophic factor in cultured rat microglia
Altschuler et al. Rescue and regrowth of sensory nerves following deafferentation by neurotrophic factors
Horner et al. Regenerating the damaged central nervous system
Koutsoudaki et al. Demyelination of the hippocampus is prominent in the cuprizone model
Bähr et al. Astrocytes from adult rat optic nerves are nonpermissive for regenerating retinal ganglion cell axons
Sherafat et al. Electromagnetic field stimulation potentiates endogenous myelin repair by recruiting subventricular neural stem cells in an experimental model of white matter demyelination
Brothers et al. Riluzole partially rescues age-associated, but not LPS-induced, loss of glutamate transporters and spatial memory
DE69821629T2 (de) Kombinationen von Cytokinen mit neurotroper Aktivität
DE68908971D1 (de) Verwendung von physiologisch wirksamen Substanzen zur Herstellung von Medikamenten für Gehirn- und Nervenerkrankungen.
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
NO940084L (no) Fremgangsmåte for behandling av motor-neuron sykdommer ved anvendelse av medlemmer av BDNF/NT-3/NGF familien av molekyler
Giap et al. The hippocampus: anatomy, pathophysiology, and regenerative capacity
Mitsumoto et al. Effects of cardiotrophin‐1 (CT‐1) in a mouse motor neuron disease
Engele et al. Effects of glial cell line-derived neurotrophic factor (GDNF) on dopaminergic neurons require concurrent activation of cAMP-dependent signaling pathways
Garg et al. IFN‐γ and IL‐4 differentially shape metabolic responses and neuroprotective phenotype of astrocytes
Fox et al. The modulations of NCAM polysialylation state that follow transient global ischemia are brief on neurons but enduring on glia
Zyuz'kov Targeted regulation of intracellular signal transduction: a new paradigm for stimulation of neurogenesis in Alzheimer's disease
Huang et al. The macroscopic and microscopic effect of low-frequency whole-body vibration after cerebral ischemia in rats
Levison et al. Ciliary neurotrophic factor stimulates nuclear hypertrophy and increases the GFAP content of cultured astrocytes
Gądek-Michalska et al. Psychosocial stress inhibits additional stress-induced hyperexpression of NO synthases and IL-1β in brain structures
Schiene et al. Enlargement of cortical vibrissa representation in the surround of an ischemic cortical lesion
Kim et al. Midkine, heparin-binding growth factor, blocks kainic acid-induced seizure and neuronal cell death in mouse hippocampus
DE59610205D1 (de) Anwendung eines medikaments und verwendung eines stoffgemischs zur herstellung eines medikaments
Tsuzaka et al. Role of brain‐derived neurotrophic factor in wobbler mouse motor neuron disease
Bates Relevance of animal-avoidance analogue studies to the treatment of clinical phobias: A rejoinder to Cooper, Furst, and Bridger.